Medical management of vascular anomalies

Facial Plastic Surgery

Volumn 28, Issue 6, 2012, Pages 575-583

  Blei, Francine ^a  

^a Vascular Birthmark Institute of New York   (United States)

Author keywords

hemangioma; vascular anomalies; vascular malformation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ARTICLE; CONGENITAL BLOOD VESSEL MALFORMATION; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMAN; KAPOSI SARCOMA; KASABACH MERRITT SYNDROME; SKIN TUMOR;

ADRENERGIC BETA-ANTAGONISTS; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMANS; KASABACH-MERRITT SYNDROME; PROPRANOLOL; SARCOMA, KAPOSI; SKIN NEOPLASMS; VASCULAR MALFORMATIONS;

EID: 84870059015     PISSN: 07366825     EISSN: 10988793     Source Type: Journal    
DOI: 10.1055/s-0032-1329932     Document Type: Article

References (141)

1. Shirazi F., Cohen C., Fried L., Arbiser J. L. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol: 2007; 5 233 236
2. Adepoju O., Wong A., Kitajewski A., et al. Expression of HES and HEY genes in infantile hemangiomas. Vasc Cell: 2011; 3 19
3. Boscolo E., Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis: 2009; 12 197 207
4. Boscolo E., Mulliken J. B., Bischoff J. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol: 2011; 179 2266 2277
5. Greenberger S., Adini I., Boscolo E., Mulliken J. B., Bischoff J. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis: 2010; 13 327 335
6. Greenberger S., Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med: 2011; 1 a006460
7. Greenberger S., Yuan S., Walsh L. A., et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol: 2011; 131 2467 2476
8. Boye E., Olsen B. R. Signaling mechanisms in infantile hemangioma. Curr Opin Hematol: 2009; 16 202 208
9. Jinnin M., Ishihara T., Boye E., Olsen B. R. Recent progress in studies of infantile hemangioma. J Dermatol: 2010; 37 283 298
10. Ostergaard P., Simpson M. A., Mendola A., et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet: 2012; 90 356 362
11. Pansuriya T. C., van Eijk R., d'Adamo P., et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet: 2011; 43 1256 1261
12. Thiex R., Mulliken J. B., Revencu N., et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol: 2010; 31 775 779
13. Boon L. M., Ballieux F., Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg: 2011; 38 7 19
14. Wooderchak-Donahue W., Stevenson D. A., McDonald J., et al. Rasa1 analysis: Clinical and molecular findings in a series of consecutive cases. Eur J Med Genet: 2011; Dec 8
15. Alomari A. I. Diversion venography - a modified technique in Klippel-Trenaunay syndrome: initial experience. J Vasc Interv Radiol: 2010; 21 685 689
16. Hernandez-Martin S., Lopez-Gutierrez J. C., Lopez-Fernandez S., et al. Brain perfusion SPECT in patients with PHACES syndrome under propranolol treatment. Eur J Pediatr Surg [et al] =. Z Kinderchir: 2011; Nov 3
17. Lohrmann C., Foeldi E., Langer M. Assessment of the lymphatic system in patients with diffuse lymphangiomatosis by magnetic resonance imaging. Eur J Radiol: 2011; 80 576 581
18. Maus E. A., Tan I. C., Rasmussen J. C., et al. Near-infrared fluorescence imaging of lymphatics in head and neck lymphedema. Head Neck: 2012; 34 448 453
19. Léauté-Labrèze C., Prey S., Ezzedine K. Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol: 2011; 25 1245 1253
20. Drolet B. A., Swanson E. A., Frieden I. J. Hemangioma Investigator Group Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr: 2008; 153 712 715, 715, e1
21. Léauté-Labrèze C., Dumas de la Roque E., Hubiche T., Boralevi F., Thambo J. B., Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med: 2008; 358 2649 2651 (Pubitemid 351831393)
22. Hammill A. M., Wentzel M., Gupta A., et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer: 2011; 57 1018 1024
23. McCuaig C. C., Dubois J., Powell J., et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol: 2009; 26 203 212
24. Pope E., Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol: 2010; 146 564 565
25. Swetman G. L., Berk D. R., Vasanawala S. S., Feinstein J. A., Lane A. T., Bruckner A. L. Sildenafil for severe lymphatic malformations. N Engl J Med: 2012; 366 384 386
26. Grunewald T. G., Damke L., Maschan M., et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol: 2010; 21 1733 1734
27. Baselga E., Cordisco M. R., Garzon M., Lee M. T., Alomar A., Blei F. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol: 2008; 158 1363 1370 (Pubitemid 351692874)
28. North P. E., Waner M., Mizeracki A., et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol: 2001; 137 559 570 (Pubitemid 32458438)
29. Metry D., Heyer G., Hess C., et al. PHACE Syndrome Research Conference Consensus statement on diagnostic criteria for phace syndrome. Pediatrics: 2009; 124 1447 1456
30. Stockman A., Boralevi F., Taïeb A., Léauté- Labrèze C. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology: 2007; 214 40 45 (Pubitemid 46032999)
31. Iacobas I., Burrows P. E., Frieden I. J., et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr: 2010; 157 795 801, e1-e7
32. Alomari A. I. CLOVE(S) syndrome: expanding the acronym. Am J Med Genet A: 2009; 149A 294; author reply 295
33. Faughnan M. E., Palda V. A., Garcia-Tsao G., et al. HHT Foundation International - Guidelines Working Group International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet: 2011; 48 73 87
34. Radhakrishnan K., Rockson S. G. Gorham's disease: an osseous disease of lymphangiogenesis? Ann N Y Acad Sci: 2008; 1131 203 205
35. Tan W. H., Baris H. N., Burrows P. E., et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet: 2007; 44 594 602 (Pubitemid 47441769)
36. Kasabach H., Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child: 1940; 59 1063
37. Sarkar M., Mulliken J. B., Kozakewich H. P., Robertson R. L., Burrows P. E. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg: 1997; 100 1377 1386
38. Enjolras O., Wassef M., Mazoyer E., et al. Infants with Kasabach-Merritt syndrome do not have "trueo" hemangiomas. J Pediatr: 1997; 130 631 640 (Pubitemid 27492656)
39. Gruman A., Liang M. G., Mulliken J. B., et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol: 2005; 52 616 622 (Pubitemid 40585431)
40. Kauvar A. N., Wang R. S. Laser treatment of cutaneous vascular anomalies. Lymphat Res Biol: 2004; 2 38 50 (Pubitemid 39206645)
41. Sun Z. Y., Yang L., Yi C. G., et al. Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. Med Hypotheses: 2008; 71 286 292
42. Chang E. I., Chang E. I., Thangarajah H., Hamou C., Gurtner G. C. Hypoxia, hormones, and endothelial progenitor cells in hemangioma. Lymphat Res Biol: 2007; 5 237 243
43. Xiao X., Liu J., Sheng M. Synergistic effect of estrogen and VEGF on the proliferation of hemangioma vascular endothelial cells. J Pediatr Surg: 2004; 39 1107 1110 (Pubitemid 38881174)
44. Sasaki G. H., Pang C. Y., Wittliff J. L. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg: 1984; 73 359 370 (Pubitemid 14157856)
45. Boye E., Yu Y., Paranya G., Mulliken J. B., Olsen B. R., Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest: 2001; 107 745 752 (Pubitemid 32225360)
46. Yu Y., Flint A. F., Mulliken J. B., Wu J. K., Bischoff J. Endothelial progenitor cells in infantile hemangioma. Blood: 2004; 103 1373 1375 (Pubitemid 38168651)
47. Yu Y., Fuhr J., Boye E., et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells: 2006; 24 1605 1612 (Pubitemid 44464678)
48. Dosanjh A., Chang J., Bresnick S., et al. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol: 2000; 27 441 450
49. Hansen S. L., Dosanjh A., Young D. M., Boudreau N., Hoffman W. Y. Hemangiomas and homeobox gene expression. J Craniofac Surg: 2006; 17 767 771 (Pubitemid 44174608)
50. Kageyama R., Ohtsuka T., Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development: 2007; 134 1243 1251 (Pubitemid 46710809)
51. Itinteang T., Brasch H. D., Tan S. T., Day D. J. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg: 2011; 64 759 765
52. Yaniv E., Preis M., Hadar T., Shvero J., Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope: 2009; 119 284 288
53. Pau H., Carney A. S., Walker R., Murty G. E. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol Allied Sci: 2000; 25 547 550 (Pubitemid 32002869)
54. Dresse M. F., David M., Hume H., et al. Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol: 1991; 8 329 334
55. Ortel T. L., Onorato J. J., Bedrosian C. L., Kaufman R. E. Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome. Am J Hematol: 1988; 29 44 48
56. Fernandez-Pineda I., Lopez-Gutierrez J. C., Ramirez G., Marquez C. Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors. Pediatr Hematol Oncol: 2010; 27 641 645
57. Zimmermann A. P., Wiegand S., Werner J. A., Eivazi B. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol: 2010; 74 338 342
58. Storch C. H., Hoeger P. H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol: 2010; 163 269 274
59. Trautmann K., Bethke A., Ehninger G., Folprecht G. Bevacizumab for recurrent hemangioendothelioma. Acta Oncol: 2011; 50 153 154
60. Fleagle J. M., Bobba R. K., Kardinal C. G., Freter C. E. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Am J Med Sci: 2012; 343 249 251
61. Kline R. M., Buck L. M. Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer: 2009; 52 534 536
62. Héritier S., Le Merrer M., Jaubert F., et al. Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009. Orphanet J Rare Dis: 2010; 5 3
63. Klement G., Cervi D., Orbach D., et al. Pten associated lesions regress in response to the antiangiogenic therapy with thalidomide/celebrex. Presented at: 17th International Workshop of ISSVA; June 20-24, 2008; Boston, MA
64. Perry B. N., Govindarajan B., Bhandarkar S. S., et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol: 2006; 126 2316 2322 (Pubitemid 44413180)
65. Ho N. T., Lansang P., Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol: 2007; 56 63 68 (Pubitemid 46016997)
66. Jiang C., Hu X., Ma G., et al. A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. Pediatr Dermatol: 2011; 28 259 266
67. Tremaine A. M., Armstrong J., Huang Y. C., et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol: 2012; Jan 13
68. White C. W., Sondheimer H. M., Crouch E. C., Wilson H., Fan L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med: 1989; 320 1197 1200 (Pubitemid 19124302)
69. Gonzalez D., Elizondo B. J., Haslag S., et al. Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome. J Pediatr Gastroenterol Nutr: 2001; 33 183 188 (Pubitemid 32802818)
70. Nardone G., Rocco A., Balzano T., Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther: 1999; 13 1429 1436 (Pubitemid 29516254)
71. Suver D. W., Perkins J. A., Manning S. C. Somatostatin treatment of massive lymphorrhea following excision of a lymphatic malformation. Int J Pediatr Otorhinolaryngol: 2004; 68 845 850 (Pubitemid 38581278)
72. Albiñana V., Bernabeu-Herrero M. E., Zarrabeitia R., Bernabéu C., Botella L. M. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost: 2010; 103 525 534
73. Blei F., Wilson E. L., Mignatti P., Rifkin D. B. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol: 1993; 155 568 578 (Pubitemid 23167401)
74. Tan H. H., Ge Z. Z., Gao Y. J., et al. The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. J Dig Dis: 2011; 12 349 356
75. Bauditz J., Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol: 2007; 13 5979 5984 (Pubitemid 350238263)
76. Lebrin F., Srun S., Raymond K., et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med: 2010; 16 420 428
77. Thomson K., Pinnock R., Teague L., Johnson R., Manikkam N., Drake R. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. N Z Med J: 2007; 120 U2418
78. Haisley-Royster C., Enjolras O., Frieden I. J., et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol: 2002; 24 459 462
79. Hochman M., Adams D. M., Reeves T. D. Current knowledge and management of vascular anomalies: I. Hemangiomas. Arch Facial Plast Surg: 2011; 13 145 151
80. Maguiness S. M., Frieden I. J. Current management of infantile hemangiomas. Semin Cutan Med Surg: 2010; 29 106 114
81. Buckmiller L. M., Richter G. T., Suen J. Y. Diagnosis and management of hemangiomas and vascular malformations of the head and neck. Oral Dis: 2010; 16 405 418
82. Elsas F. J., Lewis A. R. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus: 1994; 31 153 156 (Pubitemid 24218164)
83. Garzon M. C., Lucky A. W., Hawrot A., Frieden I. J. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol: 2005; 52 281 286
84. Buckmiller L. M., Francis C. L., Glade R. S. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol: 2008; 72 81 87 (Pubitemid 350198656)
85. Pope E., Krafchik B. R., Macarthur C., et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics: 2007; 119 e1239 e1247 (Pubitemid 46871240)
86. Greene A. K. Corticosteroid treatment for problematic infantile hemangioma: evidence does not support an increased risk for cerebral palsy. Pediatrics: 2008; 121 1251 1252
87. Greene A. K. Systemic corticosteroid is effective and safe treatment for problematic infantile hemangioma. Pediatr Dermatol: 2010; 27 322 323
88. Chianese J., Blei F. Corticosteroid toxicity in infants treated for endangering hemangiomas: Experience and guidelines for monitoring. Int Pediatr: 1999; 14 146 153
89. Ray W. Z., Lee A., Blackburn S. L., Lueder G. T., Leonard J. R. Pseudotumor cerebri following tapered corticosteroid treatment in an 8-month-old infant. J Neurosurg Pediatr: 2008; 1 88 90 (Pubitemid 351397000)
90. Maronn M. L., Corden T., Drolet B. A. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol: 2007; 143 1224 1225 (Pubitemid 47443399)
91. Aviles R., Boyce T. G., Thompson D. M. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc: 2004; 79 243 245 (Pubitemid 38140809)
92. Al-Mahdi H. Iris depigmentation: an unusual complication of intralesional corticosteroid injection for capillary hemangioma. Middle East Afr J Ophthalmol: 2010; 17 100 102
93. Deboer M. D., Boston B. A. Failure-to-thrive in an infant following injection of capillary hemangioma with triamcinolone acetonide. Clin Pediatr (Phila): 2008; 47 296 299 (Pubitemid 351341747)
94. Goyal R., Watts P., Lane C. M., Beck L., Gregory J. W. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology: 2004; 111 389 395 (Pubitemid 38183251)
95. Kushner B. J., Lemke B. N. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. J Pediatr Ophthalmol Strabismus: 1993; 30 397 399 (Pubitemid 24026843)
96. Ang L. P., Lee M. W., Seah L. L., Cheong P., Rootman J. Orbital cellulitis following intralesional corticosteroid injection for periocular capillary haemangioma. Eye (Lond): 2007; 21 999 1001 (Pubitemid 47062089)
97. Hogeling M., Adams S., Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics: 2011; 128 e259 e266
98. Menezes M. D., McCarter R., Greene E. A., Bauman N. M. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol: 2011; 120 686 695
99. Truong M. T., Perkins J. A., Messner A. H., Chang K. W. Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. Int J Pediatr Otorhinolaryngol: 2010; 74 1043 1048
100. Leboulanger N., Fayoux P., Teissier N., et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol: 2010; 74 1254 1257
101. Haider K. M., Plager D. A., Neely D. E., Eikenberry J., Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS: 2010; 14 251 256
102. Rosbe K. W., Suh K. Y., Meyer A. K., Maguiness S. M., Frieden I. J. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg: 2010; 136 658 665
103. Tan S. T., Itinteang T., Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg: 2010; Jul 6
104. Mazereeuw-Hautier J., Hoeger P. H., Benlahrech S., et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr: 2010; 157 340 342
105. Guo S., Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol: 2010; 128 255 256
106. Cante V., Pham-Ledard A., Imbert E., Ezzedine K., Léauté- Labrèze C. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed: 2012; 97 F155 F156
107. Chakkittakandiyil A., Phillips R., Frieden I. J., et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol: 2012; 29 28 31
108. Oranje A. P., Janmohamed S. R., Madern G. C., de Laat P. C. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology: 2011; Dec 16
109. Bonifazi E., Acquafredda A., Milano A., Montagna O., Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol: 2010; 27 195 196
110. Breur J. M., de Graaf M., Breugem C. C., Pasmans S. G. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol: 2011; 28 169 171
111. Holland K. E., Frieden I. J., Frommelt P. C., Mancini A. J., Wyatt D., Drolet B. A. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol: 2010; 146 775 778
112. Allford M. A., Brown J. L. Case report: intraoperative hypoglycaemia in a child treated with propranolol following a short preoperative fast. Eur J Anaesthesiol: 2011; 28 71 72
113. Naouri M., Schill T., Maruani A., Bross F., Lorette G., Rossler J. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol: 2010; 24 1109 1112
114. Tan S. T., Itinteang T., Leadbitter P. Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. Pediatrics: 2011; 127 e772 e776
115. Thomas J., Kumar P., Kumar D. D. Ulcerated infantile haemangioma of leg successfully treated with propranolol. J Cutan Aesthet Surg: 2011; 4 211 213
116. Missoi T. G., Lueder G. T., Gilbertson K., Bayliss S. J. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol: 2011; 129 899 903
117. Sciveres M., Marrone G., Pipitone S., et al. Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload. J Pediatr Gastroenterol Nutr: 2011; 53 693 695
118. Chamlin S. L., Haggstrom A. N., Drolet B. A., et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr: 2007; 151 684 689, 689, e1
119. Naouri M., Schill T., Maruani A., Bross F., Lorette G., Rossler J. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol: 2010; 24 1109 1112
120. Saint-Jean M., Léauté-Labrèze C., Mazereeuw-Hautier J., et al. Groupe de Recherche Clinique en Dermatologie Pédiatrique Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol: 2011; 64 827 832
121. Kim L. H., Hogeling M., Wargon O., Jiwane A., Adams S. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg: 2011; 46 759 763
122. Sugarman J. L., Mauro T. M., Frieden I. J. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol: 2002; 138 314 316 (Pubitemid 34226327)
123. Metz B. J., Rubenstein M. C., Levy M. L., Metry D. W. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol: 2004; 140 867 870 (Pubitemid 38917857)
124. Lapidoth M., Ben-Amitai D., Bhandarkar S., Fried L., Arbiser J. L. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol: 2009; 60 350 351
125. Sans V., de la Roque E. D., Berge J., et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics: 2009; 124 e423 e431
126. Storch C. H., Hoeger P. H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol: 2010; 163 269 274
127. Lamy S., Lachambre M. P., Lord-Dufour S., Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol: 2010; 53 200 208
128. Dai Y., Hou F., Buckmiller L., et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Arch Otolaryngol Head Neck Surg: 2012; 138 177 182
129. Lai M. L., Wang S. L., Lai M. D., Lin E. T., Tse M., Huang J. D. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther: 1995; 58 264 268
130. Sander T., Noll L., Zembles T., et al. Detection of cyp2c19 single nucleotide polymorphisms in patients with infantile hemangioma that predict reduced metabolism of propranolol. Presented at: 18th Congress of the International Society for the Study of Vascular Anomalies; April 21-24, 2010; Brussels, Belgium
131. Blanchet C., Nicollas R., Bigorre M., Amedro P., Mondain M. Management of infantile subglottic hemangioma: acebutolol or propranolol? Int J Pediatr Otorhinolaryngol: 2010; 74 959 961
132. Barlow C. F., Priebe C. J., Mulliken J. B., et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr: 1998; 132 3 Pt 1 527 530 (Pubitemid 28180264)
133. Michaud A. P., Bauman N. M., Burke D. K., Manaligod J. M., Smith R. J. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope: 2004; 114 1231 1236 (Pubitemid 38954577)
134. Chao Y. H., Liang D. C., Chen S. H., Wang L. Y., Yeh T. C., Liu H. C. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int: 2009; 51 469 473
135. Pérez-Valle S., Peinador M., Herraiz P., Saénz P., Montoliu G., Vento M. Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr: 2010; 99 311 315
136. Blatt J., Stavas J., Moats-Staats B., Woosley J., Morrell D. S. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer: 2010; 55 1396 1398
137. Burrows P. E., Mulliken J. B., Fishman S. J., Klement G. L., Folkman J. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J Craniofac Surg: 2009; 20 01 597 602
138. Iacobas I., Burrows P. E., Adams D. M., Sutton V. R., Hollier L. H., Chintagumpala M. M. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer: 2011; 57 321 323
139. Trenor C. C. III. Sirolimus for refractory vascular anomalies. Pediatr Blood Cancer: 2011; 57 904 905
140. Perry B., Banyard J., McLaughlin E. R., et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol: 2007; 143 504 506 (Pubitemid 46631649)
141. Frieden I. J. Infantile hemangioma research: looking backward and forward. J Invest Dermatol: 2011; 131 2345 2348